Ameriprise Financial Inc Blueprint Medicines Corp Transaction History

Ameriprise Financial Inc

  • $381 Billion
  • Q3 2024

A detailed history of Ameriprise Financial Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Ameriprise Financial Inc holds 324,614 shares of BPMC stock, worth $37.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
324,614
Previous 159,812 103.12%
Holding current value
$37.3 Million
Previous $17.2 Million 74.25%
% of portfolio
0.01%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$84.1 - $120.5 $13.9 Million - $19.9 Million
164,802 Added 103.12%
324,614 $30 Million
Q2 2024

Aug 14, 2024
BUY
$85.18 - $108.78 $7.78 Million - $9.93 Million
91,306 Added 133.28%
159,812 $17.2 Million
Q1 2024

May 15, 2024
BUY
$73.17 - $99.79 $555,360 - $757,406
7,590 Added 12.46%
68,506 $6.5 Million
Q4 2023

Feb 14, 2024
BUY
$43.96 - $92.84 $383,594 - $810,121
8,726 Added 16.72%
60,916 $5.62 Million
Q3 2023

Nov 14, 2023
BUY
$46.9 - $66.0 $189,710 - $266,970
4,045 Added 8.4%
52,190 $2.62 Million
Q2 2023

Aug 14, 2023
SELL
$42.2 - $66.37 $373,301 - $587,109
-8,846 Reduced 15.52%
48,145 $3.04 Million
Q1 2023

May 15, 2023
SELL
$37.97 - $50.0 $250,526 - $329,900
-6,598 Reduced 10.38%
56,991 $2.56 Million
Q4 2022

Feb 14, 2023
SELL
$41.06 - $66.48 $56,785 - $91,941
-1,383 Reduced 2.13%
63,589 $2.79 Million
Q3 2022

Nov 14, 2022
SELL
$49.93 - $77.7 $400,937 - $623,931
-8,030 Reduced 11.0%
64,972 $4.28 Million
Q2 2022

Aug 15, 2022
BUY
$45.23 - $70.15 $102,536 - $159,030
2,267 Added 3.2%
73,002 $3.69 Million
Q1 2022

May 16, 2022
BUY
$54.1 - $110.08 $1.14 Million - $2.31 Million
21,029 Added 42.31%
70,735 $4.52 Million
Q4 2021

Feb 14, 2022
BUY
$94.25 - $115.99 $264,371 - $325,351
2,805 Added 5.98%
49,706 $5.32 Million
Q3 2021

Nov 15, 2021
BUY
$80.98 - $109.47 $216,945 - $293,270
2,679 Added 6.06%
46,901 $4.82 Million
Q2 2021

Aug 16, 2021
BUY
$82.78 - $101.0 $217,545 - $265,428
2,628 Added 6.32%
44,222 $3.89 Million
Q1 2021

May 17, 2021
SELL
$90.71 - $108.28 $559,680 - $668,087
-6,170 Reduced 12.92%
41,594 $4.04 Million
Q4 2020

Feb 12, 2021
SELL
$92.08 - $124.48 $350,272 - $473,521
-3,804 Reduced 7.38%
47,764 $5.36 Million
Q3 2020

Nov 16, 2020
SELL
$66.45 - $92.7 $636,192 - $887,509
-9,574 Reduced 15.66%
51,568 $4.78 Million
Q2 2020

Aug 14, 2020
SELL
$57.09 - $79.27 $731,094 - $1.02 Million
-12,806 Reduced 17.32%
61,142 $4.77 Million
Q1 2020

May 15, 2020
BUY
$48.11 - $82.22 $2.38 Million - $4.06 Million
49,405 Added 201.3%
73,948 $4.33 Million
Q4 2019

Feb 14, 2020
SELL
$66.73 - $82.59 $590,026 - $730,260
-8,842 Reduced 26.48%
24,543 $1.97 Million
Q3 2019

Nov 14, 2019
SELL
$72.9 - $101.41 $2.33 Million - $3.24 Million
-31,992 Reduced 48.93%
33,385 $2.45 Million
Q2 2019

Aug 14, 2019
BUY
$73.54 - $97.8 $79,643 - $105,917
1,083 Added 1.68%
65,377 $6.17 Million
Q1 2019

May 15, 2019
BUY
$48.7 - $86.6 $2.93 Million - $5.2 Million
60,079 Added 1425.36%
64,294 $5.15 Million
Q4 2018

Feb 14, 2019
BUY
$45.57 - $74.26 $192,077 - $313,005
4,215 New
4,215 $227,000
Q3 2018

Nov 14, 2018
SELL
$58.91 - $78.32 $1.74 Million - $2.31 Million
-29,454 Closed
0 $0
Q2 2018

Aug 14, 2018
SELL
$60.96 - $101.18 $2.03 Million - $3.37 Million
-33,264 Reduced 53.04%
29,454 $1.87 Million
Q1 2018

May 15, 2018
SELL
$73.28 - $102.95 $515,817 - $724,665
-7,039 Reduced 10.09%
62,718 $5.75 Million
Q4 2017

Feb 12, 2018
BUY
$62.91 - $88.32 $975,042 - $1.37 Million
15,499 Added 28.57%
69,757 $5.26 Million
Q3 2017

Nov 07, 2017
BUY
$42.37 - $69.67 $2.3 Million - $3.78 Million
54,258
54,258 $3.78 Million

Others Institutions Holding BPMC

# of Institutions
352
Shares Held
60.7M
Call Options Held
2.25M
Put Options Held
1.18M
View Full List

About Blueprint Medicines Corp

BPMC Quotes by TradingView
  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $6.86B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email